These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 27295055

  • 1. Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours.
    Goulooze SC, Galettis P, Boddy AV, Martin JH.
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):209-16. PubMed ID: 27295055
    [Abstract] [Full Text] [Related]

  • 2. Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes.
    Giraud EL, Westerdijk K, van der Kleij MBA, Guchelaar NAD, Meertens M, Bleckman RF, Rieborn A, Mohammadi M, Roets E, Mathijssen RHJ, Huitema ADR, Koolen SLW, Gelderblom H, Moes DJAR, Reyners AKL, Touw DJ, Keizer-Heldens P, Oosten AW, van der Graaf WTA, Steeghs N, van Erp NP, Desar IME, Dutch Pharmacology Oncology Group (DPOG).
    ESMO Open; 2024 Jun; 9(6):103477. PubMed ID: 38833964
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics.
    Yu Y, DuBois SG, Wetmore C, Khosravan R.
    AAPS J; 2020 Jan 23; 22(2):31. PubMed ID: 31975150
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.
    de Wit D, van Erp NP, Khosravan R, Wiltshire R, Allred R, Demetri GD, Guchelaar HJ, Gelderblom H.
    BMC Cancer; 2014 Aug 08; 14():575. PubMed ID: 25102852
    [Abstract] [Full Text] [Related]

  • 11. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
    Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ.
    Cancer Chemother Pharmacol; 2010 Jul 08; 66(2):357-71. PubMed ID: 19967539
    [Abstract] [Full Text] [Related]

  • 12. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC, Wu CE, Chen JS, Tseng JH, Chiang KC, Liu YY, Tsai CY, Cheng CT, Chen TW, Jan YY, Yeh TS, Chen YY, Yeh CN.
    Anticancer Res; 2014 Sep 08; 34(9):5029-36. PubMed ID: 25202087
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The potential role of sunitinib in gastrointestinal cancers other than GIST.
    Grávalos C, Grande E, Gasent JM.
    Crit Rev Oncol Hematol; 2010 Oct 08; 76(1):36-43. PubMed ID: 20133148
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
    Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, Schellens JH, Voest EE, Sleijfer S, de Jonge MJ, Haanen JB, Beijnen JH, Huitema AD, Steeghs N.
    Br J Cancer; 2014 May 13; 110(10):2441-9. PubMed ID: 24736581
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.